Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review)

Oncology Letters

Volumn 9, Issue 3, 2015, Pages 1015-1026

  Fernandes, José Veríssimo ^a   Fernandes, Thales Allyrio Araújo De Medeiros ^b   de Azevedo, Jenner Chrystian Veríssimo ^c   Cobucci, Ricardo Ney Oliveira ^a   de Carvalho, Maria Goretti Freire ^d   Andrade, Vania Sousa ^a   De Araújo, Josélio Maria Galvão ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b University of the State of Rio Grande do Norte   (Brazil)

^c University Hospital Onofre Lopes   (Brazil)

^d POTIGUAR UNIVERSITY   (Brazil)

Author keywords

Carcinogenesis; Cervical cancer; Human papillomavirus; Inflammation

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CHEMOATTRACTANT; COLONY STIMULATING FACTOR 1; CXCL1 CHEMOKINE; CYCLOOXYGENASE 2; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; MICRORNA; MICRORNA 125B; MICRORNA 155; MICRORNA 21; PROTEIN KINASE R; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CANCER RISK; CELL DEATH; CELL PHAGOCYTOSIS; CELL TRANSFORMATION; CHLAMYDIA TRACHOMATIS; CHRONIC INFLAMMATION; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DNA DAMAGE; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEOPLASM; ONCOGENE RAS; ONCOGENE SRC; PERSISTENT INFECTION; PROTEIN EXPRESSION; REVIEW; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; UTERINE CERVIX CANCER; UTERINE CERVIX MUCOSA; VIRUS CARCINOGENESIS; VIRUS ONCOGENE; WART VIRUS;

EID: 84921750480     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.2884     Document Type: Review

References (120)

1. Ashley NT, Weil ZM and Nelson RJ: Inflammation: mechanisms, costs, and natural variation. Ann Rev Ecol Evol Syst 43: 385-406, 2012.
2. Medzhitov R: Origin and physiological roles of inflammation. Nature 454: 428-435, 2008.
3. Graham BS: Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239: 149-166, 2011.
4. Martinon F, Mayor A and Tschopp J: The inflammasomes: guardians of the body. Annu Rev Immunol 27: 229-265, 2009.
5. Nathan, C: Points of control in inflammation. Nature 420: 846-852, 2002.
6. Adefuye A and Sales K: Regulation of inflammatory pathways in cancer and infectious disease of the cervix. Scientifica (Cairo) 2012: 548150, 2012.
7. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
8. Schottenfeld D and Beebe-Dimmer JL: Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions. Ann Rev Public Health 26: 37-60, 2005.
9. Akagi K, Li J, Broutian TR, Padilla-Nash H, et al: Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res 24: 185-199, 2014.
10. Trottier H and Franco EL: The epidemiology of genital human papillomavirus infection. Vaccine 24 (Suppl 1): S1-S15, 2006.
11. Muñoz N, Castellsagué X, de González AB and Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine 24 (Suppl 3): S1-S10, 2006.
12. Mazibrada J, Rittà M, Mondini M, et al: Interaction between inflammation and angiogenesis during different stages of cervical carcinogenesis. Gynecol Oncol 108: 112-120, 2008.
13. Paghini BC, Abdalla DR, Barcelos AC, et al: Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. Hum Immunol 73: 920-926, 2012.
14. Graham CS, Wells A, Liu T, et al: Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS 19: 767-773, 2005.
15. Tang T, Wong HK, Gu W, et al: MicroRNA-182 plays an onco-miRNA role in cervical cancer. Gynecol Oncol 129: 199-208, 2013.
16. Viviani B, Bartesaghi S, Gardoni F, et al: Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci 23: 8692-8700, 2003.
17. Pasparakis, M: Regulation of tissue homeostasis by NF-kappaB signaling: implications for inflammatory diseases. Nat Rev Immunol 9: 778-788, 2009.
18. Lou JL, Maeda S, Hsu LC, et al: Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6: 297-305, 2004.
19. Hussain SP, Hofseth LJ and Harris CC: Radical causes of cancer. Nat Rev Cancer 3: 276-285, 2003.
20. Chen WL and Konkel JE: TGF-beta and 'adaptive' Foxp3(+) regulatory T cells. J Mol Cell Biol 2: 30-36, 2010.
21. Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129, 2001.
22. Ishihara K and Hirano T: Il-6 autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13: 357-368, 2002.
23. Jenkins BJ, Roberts AW, Greenhill CJ, et al: Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. Blood 109: 2380-2388, 2007.
24. Vicari AP and Trinchieri G: Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunol Rev 202: 223-236, 2004.
25. Mocellin S, Marincola FM and Young HA: Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78: 1043-1051, 2005.
26. Sadler AJ, and Williams BR: Interferon-inducible antiviral effectors. Nature Rev Immunol 8: 559-568, 2008.
27. González-Navajas JM, Lee J, David M and Raz E: Immunomodulatory functions of type I interferons. Nat Rev Immunol 12: 125-135, 2012.
28. Guarda G, Braun M, Staehli F, et al: Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34: 213-223, 2011.
29. Schroder K, Hertzog PJ, Ravasi T and Hume DA: Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75: 163-189, 2004.
30. Schoenborn JR and Wilson CB: Regulation of Interferon-gamma during innate and adaptive immune responses. Adv Immunol 96: 41-101, 2007.
31. Ruddy MJ, Wong GC, Liu XK, et al: Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem 279: 2559-2567, 2004.
32. Zhang Y, Ma D, Zhang Y, et al: The imbalance of Th17/Treg in patients with uterine cervical cancer. Clin Chim Acta 412: 894-900, 2011.
33. Chen Z, Ding J, Pang N, et al: The Th17/Treg balance and the expression of related cytokines in Uygur cervical cancer patients. Diagn Pathol 8: 61, 2013.
34. Cho ML, Kang JW, Moon YM, et al: STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 176: 5652-5661, 2006.
35. Hao JS and Shan BE: Immune enhancement and anti-tumour activity of IL-23. Cancer Immunol Immunother 55: 1426-1431, 2006.
36. Biet F, Locht C and Kremer L: Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med (Berl) 80: 147-162, 2002.
37. Nakanishi K: Regulation of Th1 and Th2 immune responses by IL-18. Kekkaku 77: 87-93, 2002 (Japanese).
38. Reddy P and Ferrara JL: Role of interleukin-18 in acute graft-vs-host disease. J Lab Clin Med 141: 365-371, 2003.
39. Medzhitov R: Origin and physiological roles of inflammation. Nature 454: 428-435, 2008.
40. Serhan CN and Savill J: Resolution of inflammation: the beginning programs the end. Nat Immunol 6: 1191-1197, 2005.
41. Akira S, Uematsu S and Takeuchi O: Pathogen recognition and innate immunity. Cell 124: 783-801, 2006.
42. Mogensen TH: Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 22: 240-273, 2009.
43. Roach JC, Glusman G, Rowen L, et al: The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci USA 102: 9577-9582, 2005.
44. Proell M, Riedl SJ, Fritz JH, et al: The Nod-like receptor (NLR) family: a tale of similarities and differences. PLoS One 3: e2119, 2008.
45. Friedman R and Hughes AL: Molecular evolution of the NF-kappaB signaling system. Immunogenetics 53: 964-974, 2002.
46. Ahmed AU: An overview of inflammation: mechanism and consequences. Front Biol; 6: 274-281, 2011.
47. Welsh RM, Bahl K, Marshall HD and Urban SL: Type 1 interferons and antiviral CD8 T-Cell responses. PLoS Pathog 8: e1002352, 2012.
48. Sica A and Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166, 2007.
49. Liu CY, Xu JY, Shi XY, et al: M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest 93: 844-854, 2013.
50. Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation and cancer. J Clin Invest 117: 1175-1183, 2007.
51. Sieve AN, Meeks KD, Lee S and Berg RE: A novel immunoregulatory function for IL-23: inhibition of IL-12-dependent IFN-γ production. Eur J Immunol 40: 2236-2247, 2010.
52. Rubtsov YP, Rasmussen JP, Chi EY, et al: Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28: 546-558, 2008.
53. Ouyang W, Kolls JK and Zheng Y: The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28: 454-467, 2008.
54. Koch MA, Trucker-Heard G, Perduc NR, et al: The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 10: 595-602, 2009.
55. Anthony MN, Gardner L, Marks G, et al: Factors associated with use of HIV primary care among persons recently diagnosed with HIV: examination of variables from the behavioural model of health-care utilization. AIDS Care 19: 195-202, 2007.
56. Anthony RM, Rutitzky LI, Urban JF Jr, Stadecker MJ and Gause WC: Protective immune mechanisms in helminth infection. Nat Rev Immunol 7: 975-987, 2007.
57. Graham AL: When T-helper cells don't help: immunopathology during concomitant infection. Q Rev Biol 77: 409-434, 2002.
58. Suvas S, Azkur AK, Kim BS, et al: CD4+CD25+ regulatory T cells control the severity of viral immunoinflammatory lesions. J Immunol 172: 4123-4132, 2004.
59. Belkaid Y and Tarbell K:. Regulatory T Cells in the Control of host-microorganism interactions. Ann Rev Immunol 27: 551-589, 2009.
60. Korn T, Bettelli E, Oukka M and Kuchroo VK: IL-17 and Th17 cells. Ann Rev Immunol 27: 485-517, 2009.
61. Jabbour HN, Sales KJ, Catalano RD and Norman JE: Inflammatory pathways in female reproductive health and disease. Reproduction 138: 903-919, 2009.
62. Maeda K, Yoshida K, Ichimiya I and Suzuki M: Dexamethasone inhibits tumor necrosis factor-alpha-induced cytokine secretion from spiral ligament fibrocytes. Hear Res 202: 154-160, 2005.
63. Sakurai F. Nakamura S, Akitomo K, Shibata H, et al: Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates. Mol Ther 16: 726-733, 2008.
64. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454: 436-444, 2008.
65. Karin M and Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759, 2005.
66. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006.
67. Karin M: NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 45: 355-361, 2006.
68. Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002.
69. Lou L, Li DQ, Corrales RM and Pflugfelder SC: Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens 31: 186-193, 2005.
70. Parkin DM and Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine 24 (Suppl 3): S11-S25, 2006.
71. Shukla S, Bharti AC, Mahata S, et al: Infection of human papillomavirus in cancers of different human organ sites. Indian J Med Res 130: 222-233, 2009.
72. Moody CA and Laimins LA: Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10: 550-560, 2010.
73. Fernandes JV, Araújo JMG and Fernandes TAAM: Biology and natural history of human papillomavirus infection. Open Access J Clin Trials 5: 1-12, 2013.
74. Hernádi Z, Gazdag L, Szoke K, Sápy T, Krasznai ZT and Kónya J: Duration of HPV-associated risk for high-grade cervical intraepithelial neoplasia. Eur J Obstet Gynecol Reprod Biol 125: 114-119, 2006.
75. Fernandes JV, Fernandes TAAM and de Araújo JMG: Human papillomavirus infection in adolescents. In: Handbook on Human Papillomavirus: Prevalence, Detection & Management. Smith HB (ed). Nova Science Publishers, New York, NY, pp181-212, 2013.
76. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
77. Stanley M: Immune responses to human papillomavirus. Vaccine 24 (Suppl 1): S16-S22, 2006.
78. Smith JS, Herrero R, Bosetti C, et al: Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 94: 1604-1613, 2002.
79. Smith JS, Muñoz N, Herrero R, et al: Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 185: 324-331, 2002.
80. de Abreu AL, Nogara PR, Souza RP, et al: Molecular detection of HPV and Chlamydia trachomatis infections in Brazilian women with abnormal cervical cytology. Am J Trop Med Hyg 87: 1149-1151, 2012.
81. Scott M, Stites DP and Mosciki AB: Th1 cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol 6: 751-755, 1999.
82. Adefuye A and Sales K: Regulation of inflammatory pathways in cancer and infectious disease of the cervix. Scientifica (Cairo) 2012: 548150, 2012.
83. Ambros V and Chen X: The regulation of genes and genomes by small RNAs. Development 134: 1635-1641, 2007.
84. Niwa R and Slack FJ: The evolution of animal microRNA function. Curr Opin Genet Dev 17: 145-150, 2007.
85. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714, 2009.
86. Tili E, Michaillle JJ and Croce CM: MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev 253: 167-184, 2013.
87. Trotta R, Chen L, Ciarlariello D, et al: miR-155 regulates IFN-γ production in natural killer cells. Blood 119: 3478-3485, 2012.
88. Schetter AJ, Okayama H and Harris CC: The role of microRNAs in colorectal cancer. Cancer J 18: 244-252, 2012.
89. de Visser KE, Korets LV and Coussens LM: De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411-423, 2005.
90. Viau, M and Zouali M: B-lymphocytes, innate immunity, and autoimmunity. Clin Immunol 114: 17-26, 2005.
91. Balkwill F, Charies KA and Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217, 2005.
92. Hawes SE and Kiviat NB: Are genital infections and inflammation cofactors in the pathogenesis of invasive cervical cancer? J Natl Cancer Inst 94: 1592-1593, 2002.
93. Schwebke JR and Zajackowski ME: Effect of concurrent lower genital tract infections on cervical cancer screening. Genitourin Med 73: 383-386, 1997.
94. Castle PE, Hillier SL, Rabe LK, et al: An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 10: 1021-1027, 2001.
95. Yang YC, Chang CL, Huang YW and Wang DY: Possible cofactor in cervical carcinogenesis: proliferation index of the transformation zone in cervicitis. Chang Gung Med J 24: 615-620, 2001.
96. Hammes LS, Tekmal RR, Naud P, et al: Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression - clinicopathological correlation. Gynecol Oncol 105: 157-165, 2007.
97. Kovacic MB, Katki HA, Kreimer AR and Sherman ME: Epidemiologic analysis of histologic cervical inflammation: relationship to human papillomavirus infections. Human Pathol 39: 1088-1095, 2008.
98. Sharkey DJ, Tremellen KP, Jasper MJ, et al: Seminal fluid Induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol 188: 2445-2454, 2012.
99. Manhart LS and Koutsky LZ : Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 29: 725-735, 2002.
100. Sales KJ and Jabbour HN: Cyclooxygenase enzymes and prostaglandins in reproductive tract physiology and pathology. Prostaglandins Other Lipid Mediat 71: 97-117, 2003.
101. Silva J, Cerqueira F and Medeiros R: Chlamydia trachomatis infection: implications for HPV status and cervical cancer. Arch Gynecol Obstet 289: 715-23, 2014.
102. Niebler M, Quian X, Höfler D, et al: Post-translational control of IL-1β via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLOS Pathog 9: e1003536, 2013.
103. Kemp TJ, Hildesheim A, Garcia-Piñeres A, et al: Elevated systemic levels of inflammatory cytokines in older women with persistent cervical HPV infection. Cancer Epidemiol Biomarkers Prev 19: 1954-1959, 2010.
104. Kaul R and Hirbod T: Editorial: Genital epithelial cells: foot soldiers or fashion leaders? J Leuk Biol 88: 427-429, 2010.
105. Stanley M: Pathology and epidemiology of HPV infection in females. Gynecol Oncol 117 (Suppl 2): S5-S10, 2010.
106. Karim R, Tummers B, Meyers C, et al: Human papillomavirus (HPV) upregulates t6he cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLOS Pathog 9: e1003384, 2013.
107. Senba M and Mori N: Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection. Oncol Rev 6: 135-144, 2012.
108. Senba M, Buziba N, Mori N, et al: Human papillomavirus infection induces NF-κB activation in cervical cancer: a comparison with penile cancer. Oncol Lett 2: 65-68, 2011.
109. James MA, Lee JH and Klingelhutz AJ: Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J Virol 80: 5301-5307, 2006.
110. Scott ME, Shvetsov YB, Thompson PJ, et al: Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study. Int J Cancer 133: 1187-1196, 2013.
111. Broccardo E, Lepique AP and Villa LL: The role of inflammation in HPV carcinogenesis. Carcinogenesis 31: 1905-1912, 2010.
112. Balkwill F: Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13: 135-41, 2002.
113. Stanley MA, Pett MR and Coleman N: HPV: from infection to cancer. Bioch Soc Trans 35: 1456-1460, 2007.
114. Tindle RW: Immune evasion in human papillomavirus-associated cervical cancer. Nature Rev Cancer 2: 59-65, 2002.
115. zur Hausen H: Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384: 260-265, 2009.
116. Oh JM, Kim SH, Lee YI, et al: Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Carcinogenesis 30: 144-149, 2009.
117. Bodily J and Laimins LA: Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol 19: 33-39, 2011.
118. Trinchieri G: Innate inflammation and cancer: is it time for cancer prevention? F1000 Med Rep 3: 11, 2011.
119. Sales KJ, Katz AA, Howard B, et al Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 62: 424-432, 2002.
120. Santin AD, Zhan F, Bignotti E, et al: Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virol 331: 269-291, 2005.